Neuroprotective effect of the natural iron chelator, phytic acid in a cell culture model of Parkinson's disease

Toxicology

Volumn 245, Issue 1-2, 2008, Pages 101-108

  Xu, Qi ^a   Kanthasamy, Anumantha G ^a   Reddy, Manju B ^a  

^a IOWA STATE UNIVERSITY   (United States)

Author keywords

IP6; Iron; MPP+; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; CASPASE 3; CHELATING AGENT; FERROUS SULFATE; NATURAL IRON CHELATOR; NITRILOTRIACETIC ACID; PHYTIC ACID; THIAZOLYL BLUE TETRAZOLIUM BROMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ASSAY; CELL CULTURE; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CYTOTOXICITY; DNA FRAGMENTATION; HOECHST NUCLEAR STAINING; IRON METABOLISM; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; STAINING; THIAZOLYLE BLUE TETRAZOLIUM BROMIDE; TRYPAN BLUE STAINING;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; APOPTOSIS; CASPASE 3; CELL DIFFERENTIATION; CELL SURVIVAL; CELLS, CULTURED; DNA FRAGMENTATION; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; IRON; IRON CHELATING AGENTS; MESENCEPHALON; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PHYTIC ACID; RATS;

RATTUS;

EID: 39549115452     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2007.12.017     Document Type: Article

References (49)

1. Agte V., Jahagirdar M., and Chiplonkar S. Apparent absorption of eight micronutrients and phytic acid from vegetarian meals in ileostomized human volunteers. Nutrition 21 (2005) 678-685
2. Alam Z.I., Daniel S.E., Lees A.J., Marsden D.C., Jenner P., and Halliwell B. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 69 (1997) 1326-1329
3. Bains M., Cousins J.C., and Roberts J.L. Neuroprotection by estrogen against MPP+-induced dopamine neuron death is mediated by ERalpha in primary cultures of mouse mesencephalon. Exp. Neurol. 204 (2007) 767-776
4. Beal M.F. Experimental models of Parkinson's disease. Nat. Rev. Neurosci. 2 (2001) 325-334
5. Ben-Shachar D., Eshel G., Finberg J.P., and Youdim M.B. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56 (1991) 1441-1444
6. Berg D., Becker G., Riederer P., and Riess O. Iron in neurodegenerative disorders. Neurotox. Res. 4 (2002) 637-653
7. Berg D., Gerlach M., Youdim M.B., Double K.L., Zecca L., Riederer P., and Becker G. Brain iron pathways and their relevance to Parkinson's disease. J. Neurochem. 79 (2001) 225-236
8. Bishop G.M., Robinson S.R., Liu Q., Perry G., Atwood C.S., and Smith M.A. Iron: a pathological mediator of Alzheimer disease?. Dev. Neurosci. 24 (2002) 184-187
9. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., and Verna J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65 (2001) 135-172
10. Burke R.E., and Kholodilov N.G. Programmed cell death: does it play a role in Parkinson's disease?. Ann. Neurol. 44 (1998) S126-S133
11. Cadet J.L., Katz M., Jackson-Lewis V., and Fahn S. Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res. 476 (1989) 10-15
12. Cole G.M. Ironic fate: can a banned drug control metal heavies in neurodegenerative diseases?. Neuron 37 (2003) 889-890
13. Drechsel D.A., Liang L.P., and Patel M. 1-Methyl-4-phenylpyridinium-induced alterations of glutathione status in immortalized rat dopaminergic neurons. Toxicol. Appl. Pharmacol. 220 (2007) 341-348
14. Ebadi M., Govitrapong P., Sharma S., Muralikrishnan D., Shavali S., Pellett L., Schafer R., Albano C., and Eken J. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of Parkinson's disease. Biol. Signal Recept. 10 (2001) 224-253
15. Ernster L., and Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim. Biophys. Acta 1271 (1995) 195-204
16. Floor E., and Wetzel M.G. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J. Neurochem. 70 (1998) 268-275
17. Graf E., and Eaton J.W. Antioxidant functions of phytic acid. Free Radic. Biol. Med. 8 (1990) 61-69
18. Graf E., Empson K.L., and Eaton J.W. Phytic acid. A natural antioxidant. J. Biol. Chem. 262 (1987) 11647-11650
19. Graf E., Mahoney J.R., Bryant R.G., and Eaton J.W. Iron-catalyzed hydroxyl radical formation. Stringent requirement for free iron coordination site. J. Biol. Chem. 259 (1984) 3620-3624
20. Grases F., Simonet B.M., Prieto R.M., and March J.G. Phytate levels in diverse rat tissues: influence of dietary phytate. Br. J. Nutr. 86 (2001) 225-231
21. Grunblatt E., Mandel S., and Youdim M.B. Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP. Ann. N.Y. Acad. Sci. 899 (2000) 262-273
22. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 53 Suppl. 3 (2003) S26-S36 Discussion S36-8
23. Jenner P., and Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47 (1996) S161-S170
24. Kalivendi S.V., Kotamraju S., Cunningham S., Shang T., Hillard C.J., and Kalyanaraman B. 1-Methyl-4-phenylpyridinium (MPP+)-induced apoptosis and mitochondrial oxidant generation: role of transferrin-receptor-dependent iron and hydrogen peroxide. Biochem. J. 371 (2003) 151-164
25. Kanthasamy A.G., Sharma N., Kirby M.L., and Schwarzschild M.A. Neuroprotective strategies in Parkinson's disease. Neuroprotection: Basic & Clinical Aspects (2001), Prominent Press pp. 604-640
26. Kaul S., Kanthasamy A., Kitazawa M., Anantharam V., and Kanthasamy A.G. Caspase-3 dependent proteolytic activation of protein kinase C delta mediates and regulates 1-methyl-4-phenylpyridinium (MPP+)-induced apoptotic cell death in dopaminergic cells: relevance to oxidative stress in dopaminergic degeneration. Eur. J. Neurosci. 18 (2003) 1387-1401
27. Kaur D., and Andersen J.K. Ironing out Parkinson's disease: is therapeutic treatment with iron chelators a real possibility?. Aging Cell 1 (2002) 17-21
28. Kaur D., Yantiri F., Rajagopalan S., Kumar J., Mo J.Q., Boonplueang R., Viswanath V., Jacobs R., Yang L., Beal M.F., DiMonte D., Volitaskis I., Ellerby L., Cherny R.A., Bush A.I., and Andersen J.K. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37 (2003) 899-909
29. Kontoghiorghes G.J. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs. Toxicol. Lett. 80 (1995) 1-18
30. Lan J., and Jiang D.H. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J. Neural. Transm. 104 (1997) 469-481
31. Latchoumycandane C., Anantharam V., Kitazawa M., Yang Y., Kanthasamy A., and Kanthasamy A.G. Protein kinase Cdelta is a key downstream mediator of manganese-induced apoptosis in dopaminergic neuronal cells. J. Pharmacol. Exp. Ther. 313 (2005) 46-55
32. Lee D.W., Andersen J.K., and Kaur D. Iron dysregulation and neurodegeneration: the molecular connection. Mol. Interv. 6 (2006) 89-97
33. Liu G., Men P., Harris P.L., Rolston R.K., Perry G., and Smith M.A. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci. Lett. 406 (2006) 189-193
34. Moon Y., Lee K.H., Park J.H., Geum D., and Kim K. Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q10. J. Neurochem. 93 (2005) 1199-1208
35. Obata T. Phytic acid suppresses 1-methyl-4-phenylpyridinium ion-induced hydroxyl radical generation in rat striatum. Brain Res. 978 (2003) 241-244
36. Prasad K.N., Cole W.C., and Kumar B. Multiple antioxidants in the prevention and treatment of Parkinson's disease. J. Am. Coll. Nutr. 18 (1999) 413-423
37. Reddy M.B., Hurrell R.F., Juillerat M.A., and Cook J.D. The influence of different protein sources on phytate inhibition of nonheme-iron absorption in humans. Am. J. Clin. Nutr. 63 (1996) 203-207
38. Reddy N.R., and Sathe S.K. Food Phytates (2002), CRC Press, Boca Raton
39. Samii A., Nutt J.G., and Ransom B.R. Parkinson's disease. Lancet 363 (2004) 1783-1793
40. Schafer F.Q., Qian S.Y., and Buettner G.R. Iron and free radical oxidations in cell membranes. Cell Mol. Biol. (Noisy-le-grand) 46 (2000) 657-662
41. Scheife R.T., Schumock G.T., Burstein A., Gottwald M.D., and Luer M.S. Impact of Parkinson's disease and its pharmacologic treatment on quality of life and economic outcomes. Am. J. Health Syst. Pharm. 57 (2000) 953-962
42. Shamsuddin A.M., and Vucenik I. Mammary tumor inhibition by IP6: a review. Anticancer Res. 19 (1999) 3671-3674
43. Shamsuddin A.M., Vucenik I., and Cole K.E. IP6: a novel anti-cancer agent. Life Sci. 61 (1997) 343-354
44. Vucenik I., and Shamsuddin A.M. Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic. J. Nutr. 133 (2003) 3778S-3784S
45. Vucenik I., Tomazic V.J., Fabian D., and Shamsuddin A.M. Antitumor activity of phytic acid (inositol hexaphosphate) in murine transplanted and metastatic fibrosarcoma, a pilot study. Cancer Lett. 65 (1992) 9-13
46. Yang Y., Kaul S., Zhang D., Anantharam V., and Kanthasamy A.G. Suppression of caspase-3-dependent proteolytic activation of protein kinase C delta by small interfering RNA prevents MPP+-induced dopaminergic degeneration. Mol. Cell Neurosci. 25 (2004) 406-421
47. Zecca L., Gallorini M., Schunemann V., Trautwein A.X., Gerlach M., Riederer P., Vezzoni P., and Tampellini D. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neurochem. 76 (2001) 1766-1773
48. Zhang D., Kanthasamy A., Yang Y., Anantharam V., and Kanthasamy A. Protein kinase C delta negatively regulates tyrosine hydroxylase activity and dopamine synthesis by enhancing protein phosphatase-2A activity in dopaminergic neurons. J. Neurosci. 27 (2007) 5349-5362
49. Zhang X., Xie W., Qu S., Pan T., Wang X., and Le W. Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration. Biochem. Biophys. Res. Commun. 333 (2005) 544-549